Related scientific articles (all)

Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.

Authors : Lambertini M, Ceppi M, Anderson RA, Cameron DA, Bruzzone M, Franzoi MA, Massarotti C, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn J, Latocca MM, Arecco L, Pistilli B, Ruddy KJ, Ballestrero A, Del Mastro L, Peccatori FA, Partridge AH, Saura C, Untch M, Piccart-Gebhart M, Di Cosimo S, de Azambuja E, Demeestere I
Year : 2023
Journal : J Natl Compr Canc Netw
Volume : 21
Pages : 33-41.e16

Approaches to Fertility Preservation for Young Women With Breast Cancer.

Authors : Razeti MG, Soldato D, Arecco L, Levaggi A, Puglisi S, Solinas C, Agostinetto E, Spinaci S, Lapuchesky L, Genova C, Massarotti C, Lambertini M
Year : 2023
Journal : Clin Breast Cancer
Volume : 23
Pages : 241-248

Reply to S. Di Cosimo et al.

Authors : Agostinetto E, Venet D, Ignatiadis M, Kalashnikova E
Year : 2023
Journal : JCO Precis Oncol
Volume : 7
Pages : e2200644

Medical oncology education in Europe: equipping medical oncologists to provide the best care for patients with cancer.

Authors : Jordan K, de Azambuja E, Amaral T, Strijbos M, Curigliano G, Lordick F
Year : 2023
Journal : Oncol Res Treat

Food in painting: From dietetics to symbolism.

Authors : Van Gossum A
Year : 2023
Journal : Clin Nutr ESPEN
Volume : 54
Pages : 374-381

Immunotherapy in breast cancer: an overview of current strategies and perspectives.

Authors : Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, Buisseret L
Year : 2023
Journal : NPJ Breast Cancer
Volume : 9
Pages : 7

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials.

Authors : Pala L, De Pas T, Pagan E, Sala I, Catania C, Zattarin E, Arnone P, Grassi MM, Colleoni M, Wolff AC, Cortes J, Piccart-Gebhart M, Gelber Rd, Viale G, Bagnardi V, Conforti F
Year : 2023
Journal : Breast
Volume : 69
Pages : 258-264

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

Authors : de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T
Year : 2023
Journal : ESMO Open
Volume : 8
Pages : 100772

ASO Visual Abstract: The Prognostic Value of Distinct Histological Growth Patterns of Colorectal Peritoneal Metastases-A Pilot Study.

Authors : El Asmar A, Demetter P, Fares F, Sclafani F, Hendlisz A, Donckier V, Vermeulen P, Liberale G
Year : 2023
Journal : Ann Surg Oncol

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.

Authors : Loibl S, Loirat D, Tolaney SM, Punie K, Oliveira M, Rugo HS, Bardia A, Hurvitz SA, Brufsky AM, Kalinsky K, Cortés J, OShaughnessy JA, Dieras V, Carey LA, Gianni L, Gharaibeh M, Preger L, Phan S, Chang L, Shi L, Piccart-Gebhart M
Year : 2023
Journal : Eur J Cancer
Volume : 178
Pages : 23-33

PIK3CA copy number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer.

Authors : Amato O, Buisseret L, Gebhart G, Plouznikoff N, Larsimont D, Awada A, Piccart M, Aftimos P
Year : 2023
Journal : Cold Spring Harb Mol Case Stud

Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab.

Authors : Orte Cano C, Van Meerhaeghe T, Tannous J, Lienard D, Van Gestel D, Cuylits N, Luce S, Carlot S, Le Moine A, Aspeslagh S, Del Marmol V
Year : 2022
Journal : J Eur Acad Dermatol Venereol
Volume : 36 Suppl 1
Pages : 53-58

Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.

Authors : Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D
Year : 2022
Journal : Cancer Treat Rev
Volume : 111
Pages : 102468

MONARCH-plus: the evidence of efficacy and safety of abemaciclib in countries with limited clinical research opportunitie

Authors : Awada A, Gombos A
Year : 2022
Journal : TBCR
Volume : -
Pages : 4 pages

Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab.

Authors : Bachir B, Anouti S, Abi Jaoude J, Kayali M, Tfayli A, de Azambuja E, Poortmans P, Zeidan YH
Year : 2022
Journal : Int J Radiat Oncol Biol Phys
Volume : 113
Pages : 135-142

Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.

Authors : Akin Telli T, Bregni G, Vanhooren M, Saude Conde R, Hendlisz A, Sclafani F
Year : 2022
Journal : Cancer Treat Rev
Volume : 110
Pages : 102460

Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance.

Authors : Kehagias P, Kindt N, Krayem M, Najem A, Agostini G, Acedo Reina E, Bregni G, Sclafani F, Journe F, Awada A, Ghanem GE, Hendlisz A
Year : 2022
Journal : Cells
Volume : 11

Deep Epigastric Lymph Nodes Implication in Patients' Recurrence Pattern After Cytoreductive Surgery in Colorectal Peritoneal Metastases.

Authors : El Asmar A, Vouche M, Galdon MG, Bali MA, Sclafani F, Donckier V, Liberale G
Year : 2022
Journal : J Gastrointest Surg
Volume : 26
Pages : 1314-1317

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.

Authors : Awada A, Berghmans T, Clement PM, Cuppens K, De Wilde B, Machiels JP, Pauwels P, Peeters M, Rottey S, van Cutsem E
Year : 2022
Journal : Crit Rev Oncol Hematol
Volume : 169
Pages : 103564

Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer.

Authors : Spira A, Awada A, Isambert N, Lorente D, Penel N, Zhang Y, Ojalvo LS, Hicking C, Rolfe PA, Ihling C, Dussault I, Locke G, Borel C
Year : 2022
Journal : Front Oncol
Volume : 12
Pages : 981940